AM 803

Known as: AM-803, GSK2190915 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2013
02420132013

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Exercise-induced bronchoconstriction (EIB) describes the condition whereby exercise causes airflow obstruction that lasts for up… (More)
Is this relevant?
2014
2014
Patients with refractory asthma frequently have neutrophilic airway inflammation and respond poorly to inhaled corticosteroids… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
2014
2014
Pharmacokinetic variability in drug exposure is a concern for all compounds in development including those for the treatment of… (More)
Is this relevant?
2013
2013
BACKGROUND GSK2190915, a potent 5-lipoxygenase-activating protein inhibitor, prevents the synthesis of leukotrienes and 5-oxo-6,8… (More)
Is this relevant?
2013
2013
BACKGROUND GSK2190915 is a high affinity 5-lipoxygenase-activating protein inhibitor being developed for the treatment of asthma… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2013
2013
AIM To assess the pharmacokinetics, pharmacodynamics, safety and tolerability of the 5-lipoxygenase-activating protein inhibitor… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 3
Is this relevant?
2013
2013
OBJECTIVE To investigate the clinical benefits of 'add-on' therapy with GSK2190915 in combination with the inhaled corticosteroid… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2013
2013
BACKGROUND GSK2190915, a 5-lipoxygenase activating protein inhibitor, inhibits the production of cysteinyl leukotrienes and… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?